Active ingredient
Ustekinumab NDC Codes
Ustekinumab is an active ingredient in 41 finished products listed with the FDA, under 11 names.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Brand and generic names
- Wezlana, Pyzchiva, Steqeyma, Starjemza, Otulfi, Ustekinumab-Ttwe, Yesintek, ustekinumab, Stelara, Ustekinumab-Aauz, Selarsdi
- Labelers
- Nuvaila Limited, Fresenius Kabi USA, LLC, Janssen Biotech, Inc., CELLTRION USA, Inc., Hikma Pharmaceuticals USA Inc., Quallent Pharmaceuticals Health LLC, Biocon Biologics Inc., SANDOZ INC, Cordavis Limited, A-S Medication Solutions
- Strengths
- Ustekinumab 45 mg/.5mL; Ustekinumab 90 mg/mL; Ustekinumab 130 mg/26mL
- Dosage forms
- Injection, Solution, Injection, Solution
- Routes
- Subcutaneous, Intravenous
- Drug classes (FDA established)
- Interleukin-12 Antagonist, Interleukin-23 Antagonist
- Package NDCs
- 49
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|---|
| Steqeymaustekinumab-stba | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | CELLTRION USA, Inc. | 72606-060 | 72606-0060-01 | J3357 |
| Ustekinumab-Aauz | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Fresenius Kabi USA, LLC | 65219-862 | 65219-0862-01 | J3357 |
| Ustekinumab-Aauz | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Fresenius Kabi USA, LLC | 65219-866 | 65219-0866-26 | J3357 |
| Starjemzaustekinumab-hmny | Ustekinumab 45 mg/.5mL | InjectionSubcutaneous | Hikma Pharmaceuticals USA Inc. | 0143-9168 | 00143-9168-01 | J3357 |
| Starjemzaustekinumab-hmny | Ustekinumab 45 mg/.5mL | InjectionSubcutaneous | Hikma Pharmaceuticals USA Inc. | 0143-9169 | 00143-9169-01 | J3357 |
| Starjemzaustekinumab-hmny | Ustekinumab 90 mg/mL | InjectionSubcutaneous | Hikma Pharmaceuticals USA Inc. | 0143-9170 | 00143-9170-01 | J3357 |
| Starjemzaustekinumab-hmny | Ustekinumab 130 mg/26mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9171 | 00143-9171-01 | — |
| Otulfiustekinumab-aauz | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Fresenius Kabi USA, LLC | 65219-822 | 65219-0822-05 | J3357 |
| Pyzchivaustekinumab-ttwe | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-651 | 83457-0651-0183457-0651-96 | J3357 |
| Pyzchivaustekinumab-ttwe | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-652 | 83457-0652-0183457-0652-96 | J3357 |
| Ustekinumab-Ttwe | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Quallent Pharmaceuticals Health LLC | 82009-160 | 82009-0160-11 | J3357 |
| Ustekinumab-Ttwe | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Quallent Pharmaceuticals Health LLC | 82009-161 | 82009-0161-94 | J3357 |
| Ustekinumab-Ttwe | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Quallent Pharmaceuticals Health LLC | 82009-162 | 82009-0162-11 | J3357 |
| Ustekinumab-Ttwe | Ustekinumab 130 mg/26mL | Injection, SolutionIntravenous | Quallent Pharmaceuticals Health LLC | 82009-163 | 82009-0163-94 | — |
| ustekinumab | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Janssen Biotech, Inc. | 57894-440 | 57894-0440-0157894-0440-03 | J3357 |
| ustekinumab | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Janssen Biotech, Inc. | 57894-441 | 57894-0441-01 | J3357 |
| ustekinumab | Ustekinumab 130 mg/26mL | SolutionIntravenous | Janssen Biotech, Inc. | 57894-444 | 57894-0444-01 | — |
| Steqeymaustekinumab-stba | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | CELLTRION USA, Inc. | 72606-027 | 72606-0027-01 | J3357 |
| Steqeymaustekinumab-stba | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | CELLTRION USA, Inc. | 72606-028 | 72606-0028-01 | J3357 |
| Steqeymaustekinumab-stba | Ustekinumab 130 mg/26mL | Injection, SolutionIntravenous | CELLTRION USA, Inc. | 72606-029 | 72606-0029-01 | — |
| Selarsdiustekinumab-aekn | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | A-S Medication Solutions | 50090-7769 | 50090-7769-00 | J3357 |
| Yesintekustekinumab | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Biocon Biologics Inc. | 83257-023 | 83257-0023-41 | J3357 |
| Pyzchivaustekinumab-ttwe | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | SANDOZ INC | 61314-651 | 61314-0651-0161314-0651-94 | J3357 |
| Pyzchivaustekinumab-ttwe | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | SANDOZ INC | 61314-652 | 61314-0652-01 | J3357 |
| Pyzchivaustekinumab-ttwe | Ustekinumab 130 mg/26mL | Injection, SolutionIntravenous | SANDOZ INC | 61314-654 | 61314-0654-94 | — |
| Yesintekustekinumab | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Biocon Biologics Inc. | 83257-024 | 83257-0024-11 | J3357 |
| Yesintekustekinumab | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Biocon Biologics Inc. | 83257-025 | 83257-0025-41 | J3357 |
| Yesintekustekinumab | Ustekinumab 130 mg/26mL | SolutionIntravenous | Biocon Biologics Inc. | 83257-026 | 83257-0026-11 | — |
| Wezlanaustekinumab-auub | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-055 | 84612-0055-01 | J3357 |
| Wezlanaustekinumab-auub | Ustekinumab 130 mg/26mL | Injection, SolutionIntravenous | Nuvaila Limited | 84612-066 | 84612-0066-01 | — |
| Wezlanaustekinumab-auub | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-076 | 84612-0076-01 | J3357 |
| Wezlanaustekinumab-auub | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-089 | 84612-0089-01 | J3357 |
| Wezlanaustekinumab-auub | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-855 | 84612-0855-01 | J3357 |
| Wezlanaustekinumab-auub | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-876 | 84612-0876-01 | J3357 |
| Wezlanaustekinumab-auub | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-889 | 84612-0889-01 | J3357 |
| Otulfiustekinumab-aauz | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Fresenius Kabi USA, LLC | 65219-824 | 65219-0824-01 | J3357 |
| Otulfiustekinumab-aauz | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Fresenius Kabi USA, LLC | 65219-826 | 65219-0826-26 | J3357 |
| Otulfiustekinumab-aauz | Ustekinumab 130 mg/26mL | SolutionIntravenous | Fresenius Kabi USA, LLC | 65219-828 | 65219-0828-05 | — |
| Stelaraustekinumab | Ustekinumab 130 mg/26mL | SolutionIntravenous | Janssen Biotech, Inc. | 57894-054 | 57894-0054-1657894-0054-27 | — |
| Stelaraustekinumab | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Janssen Biotech, Inc. | 57894-060 | 57894-0060-0257894-0060-0357894-0060-04 | J3357 |
| Stelaraustekinumab | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Janssen Biotech, Inc. | 57894-061 | 57894-0061-0357894-0061-04 | J3357 |
Ustekinumab: common questions
- Which drugs contain Ustekinumab?
- Wezlana, Pyzchiva, Steqeyma, Starjemza, Otulfi, Ustekinumab-Ttwe, Yesintek, ustekinumab, and others listed above.
- Is there a J-code for Ustekinumab?
- Med-Code's HCPCS directory matches J3357 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.